Clinical Trials

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT06764771 2026-06-03

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

GastrointestinalGenitourinaryThoracic

437 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT05633667 2026-06-01

VELOCITY-Lung

192 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07195695 2026-06-01

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Phase 3 Recruiting

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05176483 2026-05-27

STELLAR-002

GastrointestinalGenitourinaryHead & NeckThoracic

1,314 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT03520686 2026-05-26

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Terminated

102 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06561386 2026-05-20

RELATIVITY1093

Phase 3 Recruiting

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07334119 2026-05-20

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

60 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05267626 2026-05-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

159 enrolled

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Terminated

225 enrolled

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07541170 2026-05-15

KRASCENDO 3

Phase 3 Not yet recruiting

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06946797 2026-05-14

CheckMate-1533

76 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06618287 2026-05-07

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

416 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

NCT07563738 2026-05-04

TEADCO

GastrointestinalOther solid neoplasmThoracic

229 enrolled

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

NCT05867121 2026-04-27

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

GastrointestinalGenitourinaryThoracic

102 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT06544655 2026-04-17

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

GastrointestinalHead & NeckThoracic

213 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT05317858 2026-04-16

LIMITLESS

Phase 3 Recruiting

30 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07526961 2026-04-14

Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland

Completed

240 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

126 enrolled

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT02393625 2026-04-02

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

57 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04143711 2026-03-18

Study of DF1001 in Patients With Advanced Solid Tumors

Phase 1/2 Completed

270 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04423029 2026-03-18

A Study of DF6002 Alone and in Combination With Nivolumab

Phase 1 Completed

170 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT03767348 2026-02-13

IGNYTE

340 enrolled

DermatologicThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06487156 2026-01-27

FINN

Active not recruiting

404 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT07141563 2026-01-07

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

Completed

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

719 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04349267 2025-12-17

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

44 enrolled 22 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04180371 2025-11-17

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

288 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT02477826 2025-10-30

CheckMate 227

2,747 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

DermatologicGastrointestinalThoracic

463 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT03589339 2025-10-24

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

BreastGenitourinaryHead & NeckThoracic

145 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mouth Neoplasms, Oropharyngeal Neoplasms, Triple Negative Breast Neoplasms

NCT04623775 2025-10-20

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

468 enrolled 24 charts

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Phase 2 Terminated

6 enrolled 7 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

461 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT07215962 2025-10-14

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Active not recruiting

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03647163 2025-09-16

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

EndocrineGenitourinaryThoracic

33 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Neuroendocrine

NCT04278144 2025-09-15

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Phase 1/2 Terminated

175 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05076760 2025-08-29

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

BreastDermatologicGastrointestinalHead & NeckThoracic

40 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

GastrointestinalGynecologicOther solid neoplasmThoracic

57 enrolled

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Phase 1/2 Completed

145 enrolled 47 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04026412 2025-07-24

CheckMate73L

925 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT07024862 2025-06-17

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Active not recruiting

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05888831 2025-06-11

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

100 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Triple Negative Breast Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors